In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H are joined by a special guest, Bayside, a professional lobbyist who works in Washington D.C. They discuss the recent FDA announcement about the tirzepatide shortage resolution and its implications on HIMS. Bayside shares insights from his 12-page research report, which accurately predicted this outcome, and provides a detailed analysis of FDA politics, the pharmaceutical industry, and future expectations for GLP-1 compounds like semaglutide. The episode also explores potential partnerships, legal challenges, and the role of personalized medicine in the context of compounding.

00:00 Introduction

00:31 FDA Announcement and Market Reaction

00:53 Bayside's Research and Predictions

04:27 Political and Legal Implications

08:15 Semaglutide Shortage and Market Impact

19:23 Court Filings and Hims Supply Tracker

20:43 Reactions and Future Outlook

21:22 FDA Regulations and Discretion

22:35 Elon Musk's Influence and Motivations

23:31 Compounding and Personalized Medicine

26:01 Legal and Medical Perspectives on Dosage Variances

31:01 Hims and the Pharmaceutical Industry

36:25 Future of GLP-1 Drugs and Market Dynamics

41:35 Speculations and Future Partnerships

Get full access to Hims House at himshouse.substack.com/subscribe